Pharmacy Prior Authorization

AETNA BETTER HEALTH ILLINOIS FAMILY HEALTH PLAN (MEDICAID)

Orkambi (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.
Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at **1-844-242-0908**.
When conditions are met, we will authorize the coverage of Orkambi (Medicaid).
Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug Name ***(please circle)***

Orkambi (lumacaftor/ivacaftor)

Other, please specify____

Quantity ___________ Frequency ________________ Strength ___________

Route of Administration ___________ Expected Length of therapy _______________

Patient Information

Patient Name: ____________________________________

Patient ID: ____________________________________

Patient Group No.: ____________________________________

Patient DOB: ____________________________________

Patient Phone: ____________________________________

Prescribing Physician

Physician Name: ____

Specialty: ___________________________ NPI Number: _________________________

Physician Fax: ___________________________ Physician Phone: _________________________

Physician Address: ___________________________ City, State, Zip: _________________________

Diagnosis:______________________________ ICD Code:______________________________

Please circle the appropriate answer for each question.

1. Has this plan authorized Orkambi in the past for this patient (i.e., previous authorization is on file under this plan)? Y N

   [If no, skip to question 4.]

2. Has documentation been submitted to support a response to therapy (symptom improvement and/or stable FEV1)? Y N

   If yes, please document response or submit records:
   ____

   [If no, then no further questions.]

Reference Number: C8697-A / Effective Date: 08/19/2017

3. Will therapy be temporarily discontinued if the patient's AST or ALT levels are greater than 5 times the upper limit of normal? Y N

   [No further questions.]

4. Does the patient have a diagnosis of cystic fibrosis (CF)? Y N

   [If no, then no further questions.]

5. Do lab results support that the patient is homozygous for the F508del mutation at the CFTR gene? Y N

   Note: If the patient's genotype is unknown, an FDA-approved CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.

6. If yes, please provide lab results with request. Y N

   [If no, then no further questions.]

7. Is the patient 6 years of age or older? Y N

   [If no, then no further questions.]

8. Have liver function tests been evaluated and the prescribed dose reduced if the patient has moderate to severe hepatic impairment? Y N

   [If no, then no further questions.]

9. Is Orkambi being prescribed by, or in consultation with, a pulmonologist? Y N

   [If no, then no further questions.]

10. Will Orkambi be used in combination with strong CYP3A inducers such as rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, or St. John's wort? Y N

    [If yes, then no further questions.]

11. Will the patient be on other cystic fibrosis agents to manage and control symptoms (i.e., dornase alpha, tobramycin, hypertonic saline, or Cayston)? Y N

Comments:

I affirm that the information given on this form is true and accurate as of this date.

Prescriber (Or Authorized) Signature **Date**